Opus Genetics, Inc..
IRD.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Opus Genetics, Inc. is a gene therapy company focused on developing treatments for inherited retinal diseases. They are working on multiple programs targeting different genetic mutations that cause vision loss. Their approach involves developing novel gene therapies to address unmet needs in inherit...Show More
Better Health for All
0
No evidence available to assess Opus Genetics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Opus Genetics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
The provided articles do not contain sufficient specific, concrete data points to assess Opus Genetics, Inc. against the defined KPIs for Fair Pay & Worker Respect. While some articles mention executive compensation details or estimated average salaries, they do not provide reliable, company-reported data for metrics such as living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage for the general workforce.
1
Fair Trade & Ethical Sourcing
0
No evidence was found in the provided article to assess Opus Genetics, Inc. against any of the Fair Trade & Ethical Sourcing KPIs.
1
The article focuses on the company's gene therapy pipeline and does not contain information regarding supply chain practices, certifications, audits, labour incidents, traceability, or supplier diversity.
2
Honest & Fair Business
0
The provided articles do not contain specific, quantitative data points for any of the 'Honest & Fair Business' KPIs. While some articles mention the existence of a whistleblower policy and an anti-corruption policy, they explicitly state a lack of specific details or metrics regarding their strength, enforcement, training, or effectiveness, which are necessary to assign a score according to the rubric's quantitative thresholds.
1
Similarly, there is no information on regulatory fines, transparency index scores, financial restatements, audit coverage, ESG controversies, complaint resolution times, board conflict-free percentages, or third-party verification of ethical claims.
2
Kind to Animals
-40
Opus Genetics utilizes cellular models for some preclinical studies, such as demonstrating activity or stabilizing retinal degeneration for OPGx-RDH12 and OPGx-NMNAT1.
1
However, animal models, including mouse, RCS rat, canine, and larger animals, are consistently employed for preclinical safety studies, validation, and broader development across multiple gene therapy programs, including RHO-adRP, MERTK, and BEST1.
2
No specific numbers of animals used in testing are provided.
3
No War, No Weapons
10
Opus Genetics, Inc. is a gene therapy company focused on inherited retinal diseases and ophthalmic treatments. In 2024, its revenue was $10.992 million, primarily from research and development services for ophthalmic solutions.
1
The company's R&D expenses are dedicated to clinical trials, manufacturing, and personnel for its gene therapy pipeline.
2
There is no evidence of any revenue, R&D investment, or business activities related to arms, defense, or dual-use technologies.
3
The company's core business is exclusively focused on civilian medical applications.
Planet-Friendly Business
0
The provided articles explicitly state that sustainability data, including quantitative environmental performance metrics, regulatory actions, or certifications, is unavailable for IRD.US.
1
Therefore, no KPIs can be scored based on the evidence provided.
Respect for Cultures & Communities
0
The provided articles focus on Opus Genetics' gene therapy development, FDA designations, funding, internal operations, research pipeline, and patient advocacy webinars. No specific, concrete data points or information relevant to any of the KPIs under 'Respect for Cultures & Communities' were found across any of the articles. Therefore, no KPIs can be scored based on the evidence provided.
Safe & Smart Tech
10
Opus Genetics, Inc. reported no material cybersecurity threats or incidents as of March 31, 2025, indicating no breaches in the past three years.
1
The company also reported no incidents of unauthorized data use.
2
Users can request access, correction, or deletion of their personal data.
3
The company engages external providers for periodic security assessments, demonstrating good vulnerability management and security testing.
4
Opus Genetics states it has a cybersecurity risk management program based on NIST frameworks
5
and mentions compliance with various laws and regulations, including the Securities Act and Exchange Act.
6
Zero Waste & Sustainable Products
0
No evidence available to assess Opus Genetics, Inc. on Zero Waste & Sustainable Products.